MUCO® Capsules – Ambroxol 75 mg (Sustained-Release) – Medical Description

Dosage form: Sustained-release (extended-release/retard) oral capsules

Active ingredient:

• Ambroxol hydrochloride: 75 mg per capsule

Pharmacologic class: Mucolytic and expectorant agent.

Description:
MUCO capsules contain Ambroxol hydrochloride, a mucolytic medication used in respiratory disorders associated with excessive or thick mucus production. The sustained-release 75 mg formulation gradually releases the medication over approximately 24 hours, allowing prolonged activity and often once-daily administration. Ambroxol improves mucus clearance and helps make secretions easier to cough out.

Therapeutic uses:

• Productive cough associated with thick mucus
• Acute bronchitis
• Chronic bronchitis
• Respiratory disorders with difficult-to-expectorate secretions
• Conditions involving abnormal mucus production and impaired mucus transport

Mechanism of action:

• Mucolytic effect: Reduces mucus viscosity and helps break down thick bronchial secretions.
• Secretomotor activity: Enhances ciliary movement within the respiratory tract to improve mucus transport.
• Surfactant stimulation: Increases surfactant production and decreases mucus adherence within the airways.

Possible adverse effects:
Common side effects may include:

• Nausea
• Vomiting
• Abdominal discomfort
• Diarrhea
• Dry mouth
• Altered taste sensation
• Headache
• Mild gastrointestinal irritation
• Skin rash or hypersensitivity reactions

Important precautions and warnings:

• Do not use in patients with known allergy to Ambroxol or any formulation component.
• Rare severe skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported; discontinue use and seek urgent medical evaluation if rash, blistering, or mouth lesions occur.
• Use cautiously in patients with significant liver or kidney impairment.
• Sustained-release capsules should generally be swallowed whole and should not be crushed or chewed because this may alter the controlled drug release profile.

Patient Disclaimer:
This information is intended for educational and healthcare reference purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Patients should use MUCO capsules according to physician instructions or approved labeling. Seek medical attention if cough persists beyond several days, worsens, is associated with fever, shortness of breath, chest pain, or coughing blood. Patients who are pregnant, breastfeeding, have liver or kidney disease, or are taking other medications should consult a healthcare professional before use.

References (.org / academic sources):

• National Center for Biotechnology Information (NCBI/PMC): Ambroxol sustained-release pharmacokinetics and clinical use.
• Egyptian Drug Formulary: Ambroxol dosage forms and pharmacologic classification.
• Patient Information Leaflet – Ambroxol HCl 75 mg sustained-release capsules.